Screener
Aquestive Therapeutics, Inc. AQST Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebt.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
FAQ
- What is Aquestive Therapeutics, Inc.'s long-term debt?
- Aquestive Therapeutics, Inc. (AQST) reported long-term debt of $55M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s long-term debt changed year-over-year?
- Aquestive Therapeutics, Inc.'s long-term debt increased by 22.2% year-over-year, from $45M to $55M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s long-term debt?
- Over 3 years (2022 to 2025), Aquestive Therapeutics, Inc.'s long-term debt has grown at a 10.4% compound annual growth rate (CAGR), from $33.45M to $45M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Aquestive Therapeutics, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude